Gain Therapeutics (GANX) Price & Analysis

Compare

301 Followers

GANX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.41 - $3.19

Previous CloseN/A

Volume74.47K

Average Volume (3M)588.11K

Market Cap

$62.55M

Enterprise Value$48.60M

Total Cash (Recent Filing)$6.69M

Total Debt (Recent Filing)$229.17K

Price to Earnings (P/E)―

Beta1.52

Next Earnings

Nov 07, 2025

EPS Estimate

-0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.19

Shares Outstanding35,948,605

10 Day Avg. Volume623,321

30 Day Avg. Volume588,112

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.78

Enterprise Value/Revenue590.95

Enterprise Value/Gross Profit-764.05

Enterprise Value/Ebitda-2.82

Forecast

1Y Price Target

$8.00

Price Target Upside362.43% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Clinical TrialsAustralian regulators have approved extending the treatment window in the ongoing P1b study to nine months, which improves the trial's chance at showing true clinical efficacy.

Drug DevelopmentThe independent data monitoring committee reported no safety concerns and recommended continuing the study, which boosts confidence in the drug's safety profile.

Financial PositionGain Therapeutics raised $7M from a stock and warrants offering, providing financial support into early 2026 and past key trial data releases.

Bears Say

Financial PerformanceThe company reported a wider net loss than forecasted, primarily due to higher-than-expected operating expenses.

Risks And ChallengesRisks include potential delays in advancing preclinical candidates, unexpected safety issues, negative trial results, and failure to obtain regulatory approvals.

Gain Therapeutics News

Gain Therapeutics begins GT-02287 Phase 1b extension study in Parkinson’s

Gain Therapeutics (GANX) announced the start of the Phase 1b extension study allowing participants to continue treatment for...

9d ago

GANX

Gain Therapeutics receives Australian approval of Phase 1b dosing extension

Gain Therapeutics (GANX) announced the Company has received approval from the Bellberry Human Research Ethics Committee and Alfred...

23d ago

GANX

Positive Buy Rating for Gain Therapeutics Driven by Promising Clinical Trial Developments and Strong Financial Outlook

Analyst Thomas Shrader of BTIG maintained a Buy rating on Gain Therapeutics, retaining the price target of $9.00....

19d ago

GANX

Promising Developments and Regulatory Milestones Bolster Buy Rating for Gain Therapeutics

Maxim Group analyst Jason McCarthy maintained a Buy rating on Gain Therapeutics yesterday and set a price target...

22d ago

GANX

Buy Rating Reaffirmed for Gain Therapeutics Amid Promising Clinical Developments and Strong Financial Positioning

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Gain Therapeutics, with...

1M ago

GANX

Gain Therapeutics Reports Q2 2025 Financial Results

Gain Therapeutics, Inc. ( ($GANX) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

GANX

Buy Recommendation for Gain Therapeutics Driven by Promising Parkinson’s Drug Development and Strong Financial Position

Gain Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from...

1M ago

GANX

Gain Therapeutics price target lowered to $6 from $7 at Roth Capital

Roth Capital lowered the firm’s price target on Gain Therapeutics (GANX) to $6 from $7 and keeps a...

2M ago

GANX

Gain Therapeutics reports Q2 EPS (19c), consensus (17c)

“Reaching target enrollment in the Phase 1b study of GT-02287 during 2Q 2025 was an exciting achievement for...

2M ago

GANX

Gain Therapeutics Announces $7 Million Public Offering

Gain Therapeutics ( ($GANX) ) has issued an update. On July 16, 2025, Gain Therapeutics, Inc. entered into...

2M ago

GANX

Gain Therapeutics 7M share Spot Secondary priced at $1.55

Newbridge Securities acted as sole book running manager for the offering. Published first on TheFly – the ultimate...

2M ago

GANX

Gain Therapeutics prices 4.50M offering at $1.55 per share

Gain Therapeutics (GANX) announced the pricing of a public offering of 4.50M shares at $1.55 per share. Newbridge...

2M ago

GANX

Gain Therapeutics announces common stock, warrants offering

Gain Therapeutics (GANX) announced that it is proposing to offer and sell, subject to market conditions, shares of...

2M ago

GANX

Buy Rating for Gain Therapeutics Driven by Accelerated Clinical Progress and Valuation Model

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on GANX stock, giving a Buy rating yesterday....

3M ago

GANX

GANX FAQ

What was Gain Therapeutics’s price range in the past 12 months?

Gain Therapeutics lowest stock price was $1.41 and its highest was $3.19 in the past 12 months.

What is Gain Therapeutics’s market cap?

Gain Therapeutics’s market cap is $62.55M.

When is Gain Therapeutics’s upcoming earnings report date?

Gain Therapeutics’s upcoming earnings report date is Nov 07, 2025 which is in 41 days.

How were Gain Therapeutics’s earnings last quarter?

Gain Therapeutics released its earnings results on Aug 12, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.167 by -$0.023.

Is Gain Therapeutics overvalued?

According to Wall Street analysts Gain Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Gain Therapeutics pay dividends?

Gain Therapeutics does not currently pay dividends.

What is Gain Therapeutics’s EPS estimate?

Gain Therapeutics’s EPS estimate is -0.15.

How many shares outstanding does Gain Therapeutics have?

Gain Therapeutics has 35,948,605 shares outstanding.

What happened to Gain Therapeutics’s price movement after its last earnings report?

Gain Therapeutics reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.167. Following the earnings report the stock price went up 4.795%.

Which hedge fund is a major shareholder of Gain Therapeutics?

Currently, no hedge funds are holding shares in GANX

Gain Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-240.21%

Trailing 12-Months

Asset Growth

-48.77%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Gain Therapeutics

Gain Therapeutics, Inc. (GANX) is a biotechnology company operating in the healthcare sector, focusing on discovering and developing novel therapies to treat rare genetic disorders and neurological diseases. The company utilizes its proprietary SEE-Tx platform to identify and optimize allosteric binding sites on proteins, which can be targeted to restore normal function in misfolded proteins, a common cause of many serious diseases.

Gain Therapeutics (GANX) Earnings & Revenues

Historic Earnings Reports

GANX Stock 12 Month Forecast

Average Price Target

$8.00

▲(362.43% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.91,2.686153846153846,3.462307692307692,4.2384615384615385,5.014615384615385,5.790769230769231,6.566923076923077,7.343076923076923,8.11923076923077,8.895384615384616,9.671538461538463,10.447692307692309,11.223846153846154,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.91,2.378461538461538,2.8469230769230767,3.315384615384615,3.7838461538461536,4.252307692307692,4.72076923076923,5.189230769230769,5.657692307692307,6.126153846153846,6.594615384615384,7.063076923076923,7.531538461538461,{"y":8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.91,2.147692307692308,2.3853846153846154,2.623076923076923,2.8607692307692307,3.0984615384615384,3.336153846153846,3.5738461538461537,3.8115384615384613,4.049230769230769,4.286923076923077,4.524615384615385,4.762307692307692,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.06,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.64,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.16,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.13,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.18,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.57,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >